查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493202

美国核医学市场规模、份额、趋势分析报告：按产品、按应用、按最终用途、按国家、细分市场预测，2024-2030 年

U.S. Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostic (SPECT, PET), Therapeutic (Alpha, Beta Emitters, Brachytherapy)), By Application, By End-use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

美国核子医学市场成长与趋势：

Grand View Research最新报告显示，预计2030年美国核医市场规模将达122.7亿美元，2024年至2030年复合年增长率为12.6%。

这个市场主要是由癌症和心血管疾病盛行率不断上升所推动的。根据 CDC 2023 年 5 月的估计，美国每年约有 805,000 人经历心臟病发作，其中 605,000 人经历首次心臟病发作。

因此，2018年至2019年，美国政府每年在心臟病预防和治疗上的支出约为2,390亿美元。这包括药品和医疗服务的费用。某些因素，例如饮酒、饮食不当和缺乏锻炼，可能导致癌症和心臟相关疾病。因此，美国癌症和心血管疾病的发生率正在迅速增加，对核子医学的需求很可能会增加。癌症盛行率的整体上升将推动市场成长，因为接受治疗的患者数量将会增加，早期诊断和治疗的需求也会增加。

核子医学技术进步是核子医学市场的成长动力。Technetium-99m是放射性药物领域应用最广泛的放射性同位素之一。除Technetium-99m外，其他广泛使用的放射性同位素包括碘131、铟111和氟18。这些医用同位素在放射性药理学中发挥重要作用，有助于实验室中药物分布和迁移的研究。此外，FDA最近的核准预计将推动核医学市场的进一步扩大。

2023年9月，美国FDA核准Cyclopharm开发的Technegas用于核医灌注/通气肺部扫描，以诊断肺动脉栓塞。使用 Techne 气体技术的通气闪烁闪烁图术使用Technetium-99m (Tc-99m) 标记的碳奈米颗粒 (CNP)。在使用伽马摄影机进行肺部成像之前，患者吸入药物生成的奈米颗粒，这些奈米颗粒使用 Cyclopharm 子公司 Cyclomedica 製造的现场发生器雾化。

对准确诊断和治疗方法的需求不断增长正在推动核医学市场的成长。目前可用的癌症治疗方案，例如化疗和放射线治疗，涉及药物和放射线的使用，但其准确性可能并不完美。此外，这些治疗方法的主要缺点是影响全身或目标区域周围的健康器官。放射性同位素优于这些技术，因为它们可以特异性靶向肿瘤而不影响周围器官。因此，与这些诊断和治疗方法相关的益处可能会推动这些领域对放射性药物的需求。越来越多的组织采取倡议来满足对核医学日益增长的需求，预计将推动市场成长。例如，2023年8月，美国国家核安局（NNSA）计划在未来20年内斥资数百亿美元，对其核子研究和生产基础设施进行现代化改造。据估计，这将扩大患者接受核医手术的机会，并改善整体健康和福祉。

癌症和心血管疾病等慢性病的盛行率不断上升，以及核子医学作为治疗这些疾病的现有治疗技术的更好选择，预计将对市场成长产生积极影响。根据美国生物技术资讯中心 (NCBI) 2023 年 3 月的数据，美国每年进行约 2,000 万例核医/影像手术。为了满足不断增长的需求，公司正在投资研发新的加速器技术、检测器系统、放射化学、影像处理软体以及用于诊断和治疗各种疾病的自动化处理模组。

美国核医市场报告亮点

  • 以产品来看，诊断产品占最大销售份额，2023年将达71.2%。这是由于存在大量患者基础以及单光子发射电脑断层扫描 (SPECT) 和正子发射断层扫描 (PET) 等先进技术的可用性。
  • 从应用来看，肿瘤学领域在市场上占据主导地位，预计在预测期内将保持其主导地位。这是由于癌症的高发生率和对放射性药物诊断的偏好。 Iomab-B（AML 适应症）等放射治疗药物可能核准，加上符合条件的患者数量增加，预计将推动市场成长。
  • 从最终用途来看，医院行业主导市场并占据最大的销售份额。预计该细分市场在预测期内将保持其主导地位。由于医院和诊所的增加，美国核子医学市场正在扩大。由于诊断和治疗疾病的住院患者数量不断增加，核医产品的需求量很大。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国核子医学市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国核子医学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 管道分析
    • 治疗次数分析

第四章美国核子医学市场：产品估算与趋势分析

  • 美国核子医学市场：产品仪表板
  • 美国核子医学市场：产品变异分析
  • 美国核子医学市场（按产品、按收益）
  • 诊断产品
  • 治疗产品

第五章美国核子医学市场：产品估算与趋势分析

  • 美国核子医学市场：产品仪表板
  • 美国核子医学市场：产品变化分析
  • 美国核子医学市场（按产品、治疗量）
  • 诊断程序
  • 神经病学
  • 肿瘤学
  • 甲状腺
  • 神经病学
  • 肿瘤学
  • 甲状腺
  • 淋巴瘤
  • 骨转移
  • 内分泌肿瘤
  • 肺部扫描
  • 其他的

第六章美国核子医学市场：最终用途估计与趋势分析

  • 美国核子医学市场：最终用途仪表板
  • 美国核子医学市场：最终用途变化分析
  • 美国核子医学市场（依最终用途、按收益）
  • 医院/诊所
  • 诊断中心
  • 其他的

第七章 竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Eckert &Ziegler
    • Curium
    • GE Healthcare
    • Jubilant Life Sciences Ltd.
    • Bracco Imaging SPA
    • Nordion（Canada）, Inc.
    • The Institute For Radioelements（IRE）
    • NTP Radioisotopes SOC Ltd.
    • EczacIbasI-Monrol
    • Lantheus Medical Imaging, Inc.
    • The Australian Nuclear Science and Technology Organization
    • Novartis（Advanced Accelerator Applications）
    • Siemens Healthineers AG
Product Code: GVR-4-68040-261-6

U.S. Nuclear Medicine Market Growth & Trends:

The U.S. nuclear medicine market size is anticipated to reach USD 12.27 billion by 2030, registering a CAGR of 12.6%, from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing incidence of cancer and cardiovascular diseases. Cardiovascular diseases are the leading cause of death for people of most ethnic and racial groups in the U.S. According to the CDC estimates in May 2023, Division for Heart Disease and Stroke Prevention, in the U.S., about 805,000 people witness heart attack annually, of these 605,000 people witness first episode of heart attack.

Therefore, the U.S. government spent around USD 239 billion every year from 2018 to 2019 on prevention and treatment of heart diseases. This includes the cost of medicines and health care services. Certain factors such as alcohol consumption, improper diet, and lack of exercise can cause cancer and heart-related diseases. Hence, the rapid increase in the incidence of cancer and cardiovascular disorders is likely to boost the demand for nuclear medicine in the U.S. The overall increase in the prevalence of cancer will likely boost the number of patients undergoing treatment, which increases the need for early diagnosis and treatment, thereby driving market growth.

Technological advancement in the nuclear medicine is a growth driver for the nuclear medicine market. Technetium-99m stands out as one of the most extensively utilized radioisotopes in the realm of radiopharmaceuticals. Alongside Technetium-99m, other widely employed radioisotopes include Iodine-131, Indium-111, and Fluorine-18. These medical isotopes play crucial roles in radiopharmacology, facilitating the study of drug distribution and movement within laboratory subjects. Furthermore, recent approvals by the FDA are anticipated to catalyze further expansion in the nuclear medicine market.

In September 2023, the U.S. FDA approved Technegas developed by Cyclopharm for use in nuclear medicine perfusion/ventilation lung scans to diagnose pulmonary embolism. Technetium-99m (Tc-99m)-labeled Carbon Nanoparticles (CNP) are used in ventilation scintigraphy using the technology Technegas. Before undergoing lung imaging with a gamma camera, patients inhale the agent-produced nanoparticles, which are then aerosolized using on-site generators manufactured by Cyclopharm's subsidiary Cyclomedica.

Rising demand for accurate diagnostic & treatment methods serves as a growth driver for the nuclear medicine market. Currently, available cancer treatment options, such as chemotherapy and radiation therapy, involve the use of drugs & radiation, which may not be completely accurate. Moreover, these therapies have a major disadvantage of affecting the whole body or the healthy organs surrounding the target site. Radioisotopes offer an advantage over these techniques as they can specifically target the tumor without affecting the surrounding body parts. Thus, benefits associated with these diagnostic and treatment procedures will likely boost the demand for radiopharmaceuticals in these fields. An increase in organizations undertaking initiatives to help address the growing need for nuclear medicine is anticipated to impel market growth. For instance, in August 2023, National Nuclear Security Administration (NNSA) was planning to spend tens of billions of dollars to modernize its nuclear-related research and production infrastructure over the next two decades in the U.S. This is expected to expand patient access to nuclear medicine procedures, which is estimated to improve their overall health and wellbeing.

Increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, and emergence of nuclear medicine as a better option to existing treatment methodologies for treatment of these diseases is anticipated to have a positive impact on market growth. According to National Center for Biotechnology Information (NCBI) in March 2023, around 20 million nuclear medicine & imaging procedures are conducted every year in the U.S. This rising volume of these procedures is expected to open new avenues in the market during the forecast period. To meet the increasing demand, companies are investing in R&D of new accelerator technology, detector systems, radiochemistry, imaging software, and automated processing modules for diagnosis and treatment of various diseases.

U.S. Nuclear Medicine Market Report Highlights:

  • Based on product, diagnostic products held the largest revenue share of 71.2% in 2023 owing to presence of large patient base and availability of advanced technologies such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)
  • Based on application, the oncology segment dominated the market and is anticipated to maintain its dominance over the forecast period. This is attributed to the high prevalence of cancer and increased preference for radiopharmaceutical diagnosis. The probable approval of radiotherapeutic agents such as Iomab-B (indicated for AML), coupled with growing target patient population, is expected to drive market growth
  • Based on end-use, the hospitals segment dominated the market and accounted for the largest revenue share. The segment is expected to continue its dominance over the forecast period. The nuclear medicine market in the U.S. is expanding due to the rise in the number of hospitals and clinics. The demand for nuclear medicine products is high owing to rising inpatient visits for diagnosis and treatment of diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Country scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. End-use
    • 2.2.4. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Nuclear Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
      • 3.2.1.2. Technological advancement in nuclear medicine
      • 3.2.1.3. Growing demand for accurate diagnostic & treatment methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations pertaining to production, storage, and usage nuclear medicines
      • 3.2.2.2. High cost associated with diagnostic and therapeutic procedures
  • 3.3. U.S. Nuclear Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
    • 3.3.5. Procedural Volume Analysis
      • 3.3.5.1. Diagnostic Procedures
      • 3.3.5.1.1. SPECT
      • 3.3.5.1.2. PET
      • 3.3.5.2. Therapeutic Procedure

Chapter 4. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Nuclear Medicine Market: Product Dashboard
  • 4.2. U.S. Nuclear Medicine Market: Product Movement Analysis
  • 4.3. U.S. Nuclear Medicine Market by Product, Revenue
  • 4.4. Diagnostic Products
    • 4.4.1. Diagnostic Products market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. SPECT
      • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.1. TC-99m
      • 4.4.2.1.2. TL-201
      • 4.4.2.1.3. GA-67
      • 4.4.2.1.4. I-123
      • 4.4.2.1.5. Other SPECT Products
    • 4.4.3. PET
      • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.1.1. F-18
      • 4.4.3.1.2. SR-82/RB-82
      • 4.4.3.1.3. Other PET products
  • 4.5. Therapeutic Products
    • 4.5.1. Therapeutic Products market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Alpha Emitters
      • 4.5.2.1. Alpha Emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.1. RA-223
      • 4.5.2.1.2. Others
    • 4.5.3. Beta Emitters
      • 4.5.3.1. Beta Emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.1.1. I-131
      • 4.5.3.1.2. Y-90
      • 4.5.3.1.3. SM-153
      • 4.5.3.1.4. Re-186
      • 4.5.3.1.5. Lu-117
      • 4.5.3.1.6. Other Beta Emitters
    • 4.5.4. Brachytherapy
      • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.1.1. Cesium-131
      • 4.5.4.1.2. Iodine-125
      • 4.5.4.1.3. Palladium-103
      • 4.5.4.1.4. Iridium-192
      • 4.5.4.1.5. Other Brachytherapy Products

Chapter 5. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Nuclear Medicine Market: Product Dashboard
  • 5.2. U.S. Nuclear Medicine Market: Product Movement Analysis
  • 5.3. U.S. Nuclear Medicine Market by Product (Procedural Volume)
  • 5.4. Diagnostic Procedures
    • 5.4.1. Diagnostic Procedures market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. SPECT
      • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. PET
      • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Therapeutic Applications
      • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Neurology
    • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Thyroid
    • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. SPECT
      • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. Therapeutic Applications
      • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Neurology
    • 5.8.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Oncology
    • 5.9.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Thyroid
    • 5.10.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.10.1.1. SPECT
      • 5.10.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.10.1.3. Therapeutic Applications
      • 5.10.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.11. Lymphoma
    • 5.11.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.12. Bone Metastasis
    • 5.12.1. Bone Metastasis market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.12.1.1. SPECT
      • 5.12.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.12.1.3. Therapeutic Applications
      • 5.12.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.13. Endocrine Tumor
    • 5.13.1. Endocrine Tumor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.14. Pulmonary Scans
    • 5.14.1. Pulmonary Scans market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.15. Others
    • 5.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Nuclear Medicine Market: End-use Estimates & Trend Analysis

  • 6.1. U.S. Nuclear Medicine Market: End-use Dashboard
  • 6.2. U.S. Nuclear Medicine Market: End-use Movement Analysis
  • 6.3. U.S. Nuclear Medicine Market by End-use, Revenue
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Diagnostic Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.6.1.1.

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Eckert & Ziegler
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Curium
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. GE Healthcare
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Jubilant Life Sciences Ltd.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Bracco Imaging S.P.A
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Nordion (Canada), Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. The Institute For Radioelements (IRE)
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. NTP Radioisotopes SOC Ltd.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. EczacIbasI-Monrol
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Lantheus Medical Imaging, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. The Australian Nuclear Science and Technology Organization
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Novartis (Advanced Accelerator Applications)
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Siemens Healthineers AG
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Nuclear Medicine Market, 2018 - 2030 (USD Million)
  • Table 3 U.S. Nuclear Medicine Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 U.S. Nuclear Medicine Market, by Product (Procedural Volume), 2018 - 2030 (Number of procedures)
  • Table 5 U.S. Nuclear Medicine Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Nuclear Medicine Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD Modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Nuclear Medicine Market: market outlook
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 U.S. Nuclear Medicine Market driver impact
  • Fig. 13 U.S. Nuclear Medicine Market restraint impact
  • Fig. 14 U.S. Nuclear Medicine Market: Product movement analysis
  • Fig. 15 U.S. Nuclear Medicine Market: Product outlook and key takeaways
  • Fig. 16 Diagnostic Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other SPECT Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 PET market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Therapeutic Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Alpha Emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Beta Emitters products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Lu-117 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other Beta Emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other Brachytherapy Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Diagnostic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 45 SPECT procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 46 PET procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 47 Therapeutic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 48 U.S. Nuclear Medicine Market: Application movement analysis
  • Fig. 49 U.S. Nuclear Medicine Market: Application outlook and key takeaways
  • Fig. 50 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 PET market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Thyroid Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Bone Metastasis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Endocrine Tumor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Pulmonary Scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. Nuclear Medicine Market: End-use movement analysis
  • Fig. 67 U.S. Nuclear Medicine Market: End-use outlook and key takeaways
  • Fig. 68 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. Nuclear Medicine Market: Country movement analysis
  • Fig. 72 U.S. Nuclear Medicine Market: Country outlook and key takeaways
  • Fig. 73 U.S. Nuclear Medicine Market share and leading players
  • Fig. 74 Market share of key market players- U.S. Nuclear Medicine Market